Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Long-term cohort studies

Topic: Genetics and APOE

Plain-language summary

The apolipoprotein E ε4 ( APOE ε4) allele is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD), yet its associated protein changes across biofluids, brain regions, and cell types remain incompletely understood. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimer’s Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). To characterise APOE ε4 effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and patient induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. In plasma, APOE ε4 carriers shared a proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this plasma signature discriminated carriers from non-carriers in an independent CSF cohort, and mediation analysis resolved a subset of these proteins into those lying upstream and downstream of AD. Carriage was also associated with greater neuropathological burden, reflected in higher Braak stages and CERAD scores. However, only limited APOE ε4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor concordance between the transcriptome and proteome. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE ε4-associated changes. These findings show that APOE ε4 is associated with a consistent proteomic signature across plasma and CSF, but its effects in the brain differ across cell types and brain regions.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Li, X. C., Finney, C. A., & Shvetcov, A. (2026). Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimer’s disease. bioRxiv. https://doi.org/10.64898/2026.08.27.746928

Vancouver

Li XC, Finney CA, Shvetcov A. Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimer’s disease. bioRxiv. 2026. doi:10.64898/2026.08.27.746928.

BibTeX

@article{li2026-04732701,
  author  = {Li, X. C. and Finney, C. A. and Shvetcov, A.},
  title   = {{Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimer’s disease}},
  journal = {bioRxiv},
  year    = {2026},
  doi     = {10.64898/2026.08.27.746928},
  url     = {https://doi.org/10.64898/2026.08.27.746928}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 1 of 2; Free to read 0 of 2. 21 of the 62 points it could be judged on, which is 34 of 100. Raw total 34 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 34 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 34 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 21 of the 62 points we could judge it on, which is 34 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (bioRxiv)
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 3 / 4 1,691 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 21 / 62 Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 21 of the 62 points we could judge it on is 34 out of 100.
Total 34 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Long-term cohort studies from nearby years

Also tagged “apoe2”

265 studies in the library carry the topic tag “apoe2”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 265 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Long-term cohort studies

See all studies in Long-term cohort studies →